Kornimate/medical-research-clean huggingface dataset:
acute effects of static stretching on the shoulder joint position sense of overhead athletes

Conditions: Healthy

Summary: the purpose of the study is to investigate the acute effects of static stretching on the shoulder joint position sense of overhead athletes.

a crossover randomized controlled trial will be conducted with 17 overhead athletes (9 males and 8 females). all of them will perform the 3 study conditions in random order: a control (5-minute rest), and static stretching of 30 or 90 seconds of muscles around the shoulder. the shoulder joint position sense will be assessed before and immediately after these conditions, and tested by active repositioning for the range of 110º of flexion, with a video camera. absolute, relative and variable angular errors will be calculated.

Eligibility criteria:
inclusion criteria: * subjects aged between 18 and 30 years * competitive overhead athletes (basketball, handball, volleyball, swimming) * normal range of motion of flexion of the shoulder exclusion criteria: * history of injury of the shoulder joint in the previous 6 months * positive shoulder joint integrity tests (anterior drawer; fulcrum test; jerk test; and sulcus sign)

Keywords: static stretching joint position sense proprioception shoulder overhead athletes
efficacy and safety study of ibi-10090 in cataract surgery patients

Conditions: Ocular Inflammation

Summary: this study will test the efficacy and safety of ibi-10090 in the treatment of ocular inflammation after cataract surgery.


Eligibility criteria:
inclusion criteria: * male or female patients 40 years of age scheduled for unilateral cataract surgery (phacoemulsification or extracapsular extraction) with posterior chamber intraocular lens implantation. exclusion criteria: * patients who have used any ocular, topical, or oral corticosteroids within 7 days prior to day 0. * patients who have used topical ocular nsaids in the study eye within 15 days prior to screening. * patients with any signs of intraocular inflammation in either eye at screening. * patients who have received any prior intravitreal injections in the study eye.

Keywords: cataract inflammation
multidisciplinary diagnosis and treatment of polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: the investigators collected clinical data and serum samples of patients with polycystic ovary syndrome (pcos) in this study, used statistical software such as spss for date analysis, and used experimental techniques such as elisa and flow cytometry to detect serum samples, aiming to explore the relationship between the body anthropometry, skin conditions, psychosomatic status, diet, sleep, exercise, glucose and lipid metabolism, gonadal hormones, and body fat distribution in patients with polycystic ovary syndrome, and to discovery new biomarkers. multidisciplinary exploration of the mechanisms of disease occurrence and development, the establishment of a pcos multicenter, multidisciplinary and multidimensional clinical research database, combined with the established statistical analysis strategy for big data and analysis, to promote the realization of more accurate personalized medicine.


Eligibility criteria:
inclusion criteria: * female aged 18- 45; exclusion criteria: * female patients younger than 18 years old or older than 45 years old; * ovulatory disorders caused by premature ovarian failure, pituitary amenorrhea, hypothalamic amenorrhea, and thyroid dysfunction; * congenital adrenal hyperplasia, reservoir hin syndrome, hyperprolactinemia, adrenal tumors and other diseases that cause hyperandrogenism; * abnormal liver or renal function((≥ 3 times of the upper limit of normal range) * type 1 diabetes, single gene mutation diabetes, or pancreatic damage diabetes or other secondary diabetes caused by diabetes; * history of malignant tumors; * severe infection, severe anemia, neutropenia and other systemic chronic diseases; * undergo total hysterectomy or ovarian adnexectomy; * mental illness, dementia or other cognitive behavioral problems; * use hypoglycemic drugs that may affect insulin resistance and androgen levels in the last 3 months, including thiazolidinediones, metformin, sglt-2, and acarbose and glp-1ra and other drugs; * use letrozole, clomiphene, oral contraceptives, glucocorticoids, gonadotropins, gonadotropin-releasing hormone agonists, anti-androgens (spironolactone, cyproterone acetate, flutamide, etc.) and other drugs for the treatment of pcos.

Keywords: polycystic ovary syndrome clinical characteristics new biomarkers multidisciplinary
clinical efficacy of bovine freeze-dried amniotic membrane on wound healing in laser treatment

Conditions: Biological Dressings

Summary: bovine amniotic membrane may show better efficacy than hydrocolloid dressing.

bovine amniotic membrane as a biological dressing can be applicable to wound after laser treatments. comparing with hydrocolloid dressing material, which is the most widely used after laser treatment now, amniotic membrane will show better efficacy. thus, with amniotic membrane, epithelization time will shorten and redness which is usually left after laser will disappear quickly.

Eligibility criteria:
inclusion criteria: * skin lesions treatable by ablative lasers * more than two skin lesions of similar size at the same area * available during the study period (2 weeks) exclusion criteria: * taking steroid or nonsteroidal antiinflammatory drug, isotretinoin * underlying diabetes mellitus, keloid or any malignancy

Keywords: laser therapy biological dressing amniotic membrane hydrocolloid bandages wound healing
prenatal non-invasive aneuploidy test utilizing snps trial

Conditions: Trisomy 13; Trisomy 18; Trisomy 21; Aneuploidy

Summary: this prospective blinded study will assess the diagnostic capability of an informatics enhanced snp based technology (parental support) to identify pregnant women who are carrying a fetus with an aneuploidy from fee floating dna in the maternal blood.

first trimester screening is the current standard of care for pregnant women in the united states. women with a high screening risk for trisomy then have invasive testing, which carries a risk of miscarriage, to definitively determine if the fetus has trisomy. because of the high false negative rate of the first trimester screening, an unacceptable number of trisomic fetuses are not detected. moreover, because of the high false positive rate, an unacceptable number of women undergo invasive follow up testing. additional screening tests are needed that combine a high sensitivity, a low false positive rate, and minimal or no risk to the fetus.

Eligibility criteria:
inclusion criteria: 1. singleton pregnancy 2. gestational age between 8 weeks 0 days and 23 weeks, 6 days by best obstetrical estimate 3. mother has a high or moderate risk for trisomy 4. mother is planning to have or has had an amniocentesis or chorionic villus sampling (cvs) procedure exclusion criteria: 1. unavailability of the father to provide a genetic sample (e.g. sperm donor, non-paternity) 2. egg donor used 3. mother or father have known chromosomal abnormalities (including known balanced translocations) 4. participation in the study in a previous pregnancy 5. pregnancy is a result of ivf with pre-implantation genetic diagnosis

Keywords: aneuploidy non-invasive prenatal diagnosis prenatal blood test prenatal aneuploidy screening trisomy 13 trisomy 18 trisomy 21 trisomy down syndrome turner syndrome edwards syndrome
improving attention in individuals with long covid-19

Conditions: Long Covid

Summary: this study is to find out if the attention processing training program is a potential treatment for brain fog symptoms, reported by people with long-covid. also investigating the feasibility of completing this program virtually.

the goal of this project is to test the feasibility, acceptability and efficacy of an attention training intervention (attention process training; apt-3) as a potential treatment for brain fog symptoms experienced by people with long-covid. there already is good empirical evidence to support the idea that the apt-3 treatment is feasible and effective in improving attention in people with acquired brain injuries, but information about its efficacy and acceptability in people with long-covid brain fog is lacking.

Eligibility criteria:
inclusion criteria: * aged 18-65 years. live in the chicagoland area * a history of confirmed sars-cov-2 infection. * subjective reports of cognitive symptoms that interfere with everyday activities, starting on or shortly after sars-cov-2 infection. * continuation or development of long-covid brain fog 3 months after the initial sars-cov-2 infection, with these symptoms lasting for at least 2 months with no other explanation. * objective attentional deficits as measured by the conners cpt-312, and/or the digit span subtest (wais- iii13). * able to use a keyboard. * able to understand and communicate in english. * able to consent independently. exclusion criteria: * being hospitalized due to covid-19 diagnosis for more than 3 days. * pre-morbid neurological conditions that could potentially affect cognition, such as parkinson's disease, alzheimer's dementia, acquired brain injury. * severe depression. * currently enrolled in cognitive training or physical exercise training. * receiving chemotherapy or radiation within last 6 months. * active substance abuse.

Keywords: covid-19 brain fog
adiponectin and circulating progenitor cells (cpc) function

Conditions: Coronary Artery Disease

Summary: adiponectin and exercise training contribute to the maintenance of a normal vascular tone by influencing vascular no bioavailability and concentration and function of endothelial progenitor cells. the molecular mechanisms are only partially understood. therefore, aim of the present study is to elucidate the effects of adiponectin on endothelial progenitor cell migration and the underlying signaling pathways. furthermore, the impact of exercise training on adiponectin-mediated endothelial progenitor cell migration will be investigated.


Eligibility criteria:
inclusion criteria: * ≤ 75 years of age * stable coronary artery disease * preserved left ventricular function * physical work capacity of ≥ 50 * successful elective percutaneous coronary intervention at study begin exclusion criteria: * diabetes mellitus * hypercholesterolemia * untreated hypertension * smoking * myocardial infarction within the last 4 weeks * significant stenosis of the left main coronary artery
a comparative, controlled study to evaluate the lay user accuracy and performance of the dip home-based dipstick analyzer

Conditions: Urine Detectable Acute and Chronic Diseases

Summary: the dip home-based dipstick analyzer (henceforth hbda) is composed of a kit and a smartphone application. the device will be provided to the subject in a simulated home-use environment. all subjects will be asked to complete the urine test by following the application guidance, including providing a urine sample and scanning the urine strip after placing it on the color-board. the user will also complete a questionnaire to collect information regarding the use of the hbda device. following the usability test performed by the lay user, the subject's urine sample will be tested by the professional user using the comparator device. the use of the hbda device will be evaluated for accuracy and identified risks. additionally, measurable usability criteria for specific, critical steps will be evaluated.


Eligibility criteria:
inclusion criteria: * men and women 18-80 years of age * subjects who are healthy or pregnant; or * subjects diagnosed with a disease that normally represents itself with an abnormal concentration of one of the following urine analytes; glucose, bilirubin, ketone (acetoacetic acid), specific gravity, blood, ph, protein, urobilinogen, leukocytes, and nitrite * subject is capable and willing to provide informed consent. * subject has facility with both hands. * subject is capable and willing to adhere to the study procedures
comparison of a laser keratome to a mechanical microkeratome

Conditions: Myopia; Astigmatism; Myopic Astigmatism

Summary: the purpose of this study was to evaluate the performance of the intralase®, a laser keratome which creates a corneal flap, and compare it to a mechanical microkeratome (amadeus™). our hypothesis is that there is no difference between the 2 devices.


Eligibility criteria:
inclusion criteria: * candidate for bilateral wavefront-guided lasik * myopia up to -7.00 d * astigmatism of 0.00 to -1.50 d exclusion criteria: * history of ocular pathology * previous ocular surgery * very large pupils (greater than 8mm diameter, infrared measurement) * thin corneas (preoperatively calculated minimal residual bed \< 250 um) * irregular astigmatism * asymmetric astigmatism * unstable refraction * any other criteria that precludes subject to undergo lasik
post operative delirium study

Conditions: Delirium

Summary: post-operative delirium happens when patients wake up from anesthesia. patients experiencing post-operative delirium are very confused, not being able to think or function "normally". these patients are hard to take care of and they tend to have more dementia as they age compared to patients who don't experience post-operative delirium. intranasal insulin has been shown to reverse confusion associated with alzheimer's disease (humans) and aids (mice). intranasal insulin has been safely administered to 1092 patients in 38 different studies. there were no cases of clinically low blood sugar and a few cases of mild nasal irritation that happened also with salt water when the subjects received multiple intranasal doses. no one has tried to reverse post-operative delirium with intranasal insulin. the delirium associated with alzheimer's disease and aids have very similar symptoms and what happens in the brain is very similar also. the investigators intent is to administer intranasal insulin to patients exhibiting post-operative delirium in order to reverse the symptoms because the investigators think that the three disease states are closely related and intranasal insulin has had some success in reversing the delirium in the other two disease states.


Eligibility criteria:
inclusion criteria: * all patients (\>65 years of age) undergoing elective surgery using vapor anesthesia displaying post-operative delirium as defined by a cam evaluation within time to pacu discharge post-surgery are eligible. * those patients 65 and older undergoing surgery using vapor anesthesia, who are consented but do not exhibit delirium and are not part of the study are still considered recruited subjects, but are not in the active study. exclusion criteria: * patients with a history of severe dementia, anoxic brain injury, or neuromuscular disorders * non-english-speaking patients * planned use of drugs that effect plasma glucose concentration during the first four hours of surgery * thiazolidinediones * hormones which may affect plasma glucose or insulin * contraceptive, diphenylhydantoin * patients with allergy to insulin * acromegaly * cushing's syndrome * hyperthyroidism and pheochromocytoma * renal impairment * pregnant and lactating women * base line blood glucose \< 3.9 mmol/l

Keywords: insulin
the effects of lowering dialysate sodium in hypertensive hemodialysis patients

Conditions: Hypertension; Arteriosclerosis; Left Ventricular Hypertrophy

Summary: unfavorably high sodium intakes remain prevalent around the world. a negative sodium gradient in hemodialysis treatment results in absolute sodium removal via diffusive transport of sodium from the blood to the dialysate, and it may be a potentially useful tool to improve sodium loading due to excess dietary sodium intake. the purpose of this study is to determine whether a in small negative sodium gradient could improve blood pressure level, arterial stiffness and left ventricular hypertrophy in hypertensive hemodialysis patients, who had been achieving and maintaining their dry weight assessed by bioimpedance spectroscopy.

a number of studies have shown that lowering dialysate sodium concentration could improve blood pressure (bp) control, and the lower bps are considered to be a result of an improvement in volume status via increasing sodium removal. however, sodium, apart from volume, may have an independent effect on bp regulation. it is speculated that a reduction in exchangeable sodium, even without a change in body water content, may improve bp control. unfortunately, as of yet, no clinical studies have actually provided the evidence in this field. in general population, dietary salt loading produces significant increase in aortic pulse wave velocity, which is reversed by lowering sodium intake. to the investigators knowledge, the effect of sodium on arterial stiffness has not been investigated in hemodialysis patients. a regression of left ventricular hypertrophy (lvh) has been achieved through strict dietary sodium restriction in hemodialysis patients. lack of effect on lvh was observed in low sodium dialysis which may be due to the shorter time interval.

Eligibility criteria:
inclusion criteria: * they had been on hd for more than 1 year. * they had had no clinical cardiovascular disease during 3 months preceding entry into the study, with left ventricular ejection fraction over 40%. * their residual daily urine output was lower than 100 ml/day. * they had achieved their dry weight assessed by bioimpedance technique and clinical examination for at least 3 months. * a mean interdialytic ambulatory bp of \>135/85 mmhg. * averaging the last six available monthly pre-dialysis plasma sodium concentrations over the preceding 12 months \>138mmol/l. exclusion criteria: * they had known acute inflammatory event, malignant disease, and the serum albumine\<30g/l. * they were diabetic and hypotension prone.

Keywords: hypertension arterial stiffness left ventricular hypertrophy
influenza virus challenge study to test monoclonal antibody tcn-032 as a treatment for influenza

Conditions: Influenza

Summary: the purpose of this study is to determine the safety and efficacy of tcn-032 given to healthy adult volunteers that have been inoculated with the influenza a virus


Eligibility criteria:
inclusion criteria: * age 18 to 45 years, inclusive. * in good health with no history of major medical conditions * female subjects must not be pregnant or nursing * have not been vaccinated for influenza virus since 2006 * serosusceptible to the challenge virus * non-smoker or current smoker willing/able to desist exclusion criteria: * presence of any significant acute or chronic, uncontrolled medical or psychiatric illness * history or evidence of autoimmune disease * any history during adulthood of asthma, history of copd, pulmonary hypertension, reactive airway disease, any chronic lung condition of any etiology), or any use of a bronchodilator or other asthma medication within adulthood * history or clinical evidence of recurrent lower respiratory tract infection * positive human immunodeficiency virus (hiv), hepatitis b (hbv), or hepatitis c (hcv) antibody screen * subject is diabetic * history of frequent epistaxis (nose bleeds) * any nasal or sinus surgery within 6 months of the screening visit * recent and/or recurrent history of autonomic dysfunction (fainting, palpitations, etc.) * any laboratory test, ecg or spirometry which is abnormal and which is deemed by the investigator(s) to be clinically significant. * any acute medical condition or significant past medical history of hepatic, renal, cardiovascular, pulmonary, gastrointestinal, haematological, locomotor, immunologic, ophthalmologic, metabolic, endocrine, or other diseases * major surgery within 3 months prior to screening visit * evidence of drug of abuse or positive urine class a drug or alcohol screen prior to admission * subjects symptomatic with hay fever * subjects with a history of significant adverse reactions/allergies * history of allergy or intolerance to oseltamivir or zanamivir. * health care workers (including doctors, nurses, medical students, and allied healthcare professionals) anticipated to have patient contact within 2 weeks of viral challenge.

Keywords: influenza monoclonal antibody
injection of hormone to enhance implantation in embryo transfer after ivf

Conditions: Infertility

Summary: the endometrium is deprived of signals form the embryo in ivf conditions. studies suggest that placing hcg into the uterus prior to embryo transfer can enhance implantation.

the study is in pilot phase, uncontrolled. the risks appear to be minimal and there are conflicting new reports being announced. a small amount of fluid with hcg is injected into the uterus. hcg is a potent signal to the uterus for preparation for implantation. this is not a funded study. three published studies suggest the approach is valid; one refutes the concept.

Eligibility criteria:
inclusion criteria: - infertility patients undergoing ivf with good expectation of two embryos day 3 or day 5. must speak and read english. includes donor eggs. exclusion criteria:abnormal uterus -

Keywords: ivf , embryo implantation, hcg
vitamin d3 supplementation for allohsct-rct

Conditions: Vitamin D Deficiency

Summary: this study is to assess whether a single oral loading dose of 100,000 iu vitamin d3 prior to allogeneic hematopoietic stem cell transplant (ahsct) can achieve optimal 25 hydroxy-vitamin d3(25-oh-d3) levels (\>75nmol/l) at one month post ahsct, and maintain adequate levels for at least three months, compared to our standard practice of 2000 iu vitamin d3 daily. 25-oh-d3 levels will be measured prior to vitamin d3 supplementation, and 30 as well as 100 days post vitamin d supplementation. we hypothesize that the intervention will prevent vitamin d insufficiency or deficiency in ahsct recipients, therefore benefit ahsct-associated morbidity, including osteoporosis.

this is a randomized non-blinded single centre prospective clinical trial designed to validate whether a single oral loading dose of 100,000 iu vitamin d3 prior to allogeneic hematopoietic stem cell transplant (ahsct) can achieve optimal 25 hydroxy-vitamin d3(25-oh-d3) levels (\>75nmol/l) at one month post ahsct, and maintain adequate levels for at least three months, compared to our standard practice of 2000 iu vitamin d3 daily. 84 patients will be enrolled. following completion of all baseline data collection, participants will be randomized 1:1 to the intervention group or the control group on the admission day for ahsct patients in the intervention group will receive a single oral loading dose of 100,000 iu vitamin d3, with subsequent vitamin d3 2000 iu daily. patients assigned to the control group will receive our current standard of care, 2000 iu vitamin d3 daily.

Eligibility criteria:
inclusion criteria: 1. patients undergoing allogeneic stem cell transplantation at the leukemia/bmt program of british columbia. 2. age greater than or equal to 18 years. 3. able to provide written informed consent. exclusion criteria: 1. hypercalcemia, hypervitaminosis d, or allergic/ sensitive to vitamin d. 2. not meeting eligibility criteria to proceed with allogeneic stem cell transplantation as per the leukemia/bmt program of bc.